Can a cancer drug stop leukemia before it starts?
NCT ID NCT06698003
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug mogamulizumab can prevent adult T-cell leukemia/lymphoma (ATL) in people infected with HTLV-1 who are at high risk. About 134 participants will receive low doses of the drug over several weeks. The goal is to see if it can reduce the virus levels in the blood enough to stop cancer from developing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mogamulizumab
What this could lead to
If successful, this could offer a way to prevent a rare but aggressive blood cancer in people carrying the HTLV-1 virus.
What could go wrong
This is a small, early-phase trial (phase 2) with only 134 participants, so results may not apply to everyone. The drug may not reduce viral load enough or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth (All protocol activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (All protocol activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (All protocol activities)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering at Basking Ridge (All protocol activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••